Highlights

  • AIM rebounded in 2025, signalling renewed investor confidence in quality small caps
    • Technology, healthcare, sustainability, and consumer recovery themes dominate 2026 outlook
    • Several AIM stocks offer recovery-driven or catalyst-led upside potential
    • Diversification across sectors helps manage volatility and liquidity risks
    • Patient investors may benefit from attractive valuations and earnings recovery

The Alternative Investment Market (AIM) continues to play a vital role in supporting emerging and high-growth companies across the UK and Europe. After a prolonged period of pressure from rising interest rates and reduced risk appetite, AIM staged a recovery in 2025, rising nearly 10% as investors rotated back into selective small-cap opportunities.

Looking ahead to 2026, tailwinds such as stabilising rates, increased corporate activity, and sector-specific demand drivers are expected to support further gains. While AIM stocks are inherently higher-risk due to lower liquidity and increased volatility, they can offer compelling upside for investors who focus on fundamentals, cash flow visibility, and clear growth catalysts.

1. Accsys Technologies (AIM:AXS)

Accsys Technologies develops sustainable, high-performance wood products using its proprietary acetylation technology, marketed under the Accoya and Tricoya brands.

Analysts expect profit growth to accelerate in 2026 as capacity expansions come online and demand for environmentally friendly construction materials improves. With recommendation prices around 61p, Accsys is viewed as undervalued relative to its long-term sustainability-driven growth potential, despite execution and cost risks.

2. Celebrus Technologies (AIM:CLBS)

Celebrus provides customer data analytics and personalization software, enabling enterprises to maximise first-party data usage in a post-cookie regulatory environment.

After heavy investment in product development, analysts see 2026 as a recovery year, with greater adoption of its cloud-based platform. Recommendation prices near 135p reflect optimism around recurring revenues and enterprise client retention.

3. Focusrite (AIM:TUNE)

Focusrite designs audio interfaces, controllers, and music software for creators, producers, and musicians.

Following a period of supply chain disruption and softer demand, analysts anticipate a profit rebound in 2026. New product launches and exposure to the creator economy position Focusrite as a niche but resilient growth stock within the AIM universe.

4. Cake Box Holdings (AIM:CBOX)

Cake Box operates a fast-growing franchise network of egg-free fresh cream cake shops across the UK.

Viewed as a consumer recovery play, the company benefits from strong brand recognition, low capital intensity, and continued franchise expansion. Analysts highlight its defensive characteristics within discretionary spending, while noting competition and cost pressures as key risks.

5. Shearwater Group (AIM:SWG)

Shearwater provides cybersecurity advisory, testing, and managed security services to mid-market and enterprise clients.

Rising cyber threats and tightening regulations are expected to drive demand in 2026. Analysts forecast profit acceleration driven by new contract wins and service diversification, positioning Shearwater as a defensive tech services growth stock.

6. hVIVO (AIM:HVO)

hVIVO specialises in human challenge trials, supporting vaccine and antiviral development through controlled clinical testing.

With a strong order book and diversified service offering, analysts see improving earnings visibility in 2026. While biotech sector volatility remains a risk, demand for faster and more efficient clinical trials supports its long-term outlook.

7. Poolbeg Pharma (AIM:POLB)

Poolbeg Pharma is a clinical-stage biotechnology company developing treatments for infectious and inflammatory diseases.

The stock is considered speculative but offers high upside potential in 2026, driven by clinical milestones and partnership opportunities. Investors should be mindful of funding requirements and trial-related risks.

8. Blue Star Capital (AIM:BLU)

Blue Star Capital is an investment company targeting high-growth opportunities across technology, media, and gaming.

Its appeal lies in portfolio revaluations and potential asset realisations. NAV growth and exposure to emerging digital sectors make it a leveraged play on AIM’s broader recovery.

9. Onward Opportunities (AIM:ONWD)

Onward Opportunities is an investment trust focused on undervalued UK small-cap and AIM-listed companies.

With a track record of NAV growth and positive industry recognition, it provides diversified exposure to a potential small-cap recovery without reliance on single-stock performance.

10. Zephyr Energy (AIM:ZPHR)

Zephyr Energy focuses on US onshore oil and gas development, supported by strategic partnerships.

Production growth and cash flow potential in 2026 underpin analyst interest, although commodity price volatility and regulatory risks remain key considerations.

Risks and Considerations

AIM stocks carry elevated risks, including lower liquidity, wider bid–ask spreads, and sensitivity to market sentiment. Economic downturns, funding constraints, or adverse news flow can have an outsized impact. Diversification, focus on cash-generative businesses, and close monitoring of company updates are essential risk management tools.

Outlook for 2026:
With improving macro conditions and selective investor rotation back into small caps, AIM offers a fertile hunting ground for growth-oriented investors. These ten stocks combine recovery potential, thematic exposure, and analyst backing, positioning them as notable candidates for 2026.

Note

The information, analysis, and stock recommendations contained in this document represent the personal views and opinions of the author and should not be attributed to, or considered as representing the views of, Kalkine Group or any of its affiliates.

This material has been prepared for general informational and educational purposes only and does not constitute financial advice, investment advice, or a recommendation to buy, sell, or hold any particular securities. The content should not be relied upon as the sole basis for any investment decision.

Important Considerations:

  • Not Financial Advice: This document does not take into account your personal objectives, financial situation, or needs. Before making any investment decisions, you should consider whether the information is appropriate for your circumstances and seek professional financial advice from a licensed advisor.
  • Past Performance: Any references to past performance of stocks, indices, or investment strategies are not indicative of future results. Stock markets are inherently volatile and investments can go down as well as up.
  • Accuracy of Information: While reasonable efforts have been made to ensure the accuracy of the information presented, the author makes no warranties or representations regarding the completeness, accuracy, or timeliness of this content. Information is based on sources believed to be reliable as of the date of publication but may become outdated.
  • Investment Risk: Investing in stocks and securities involves risk, including the potential loss of principal. Different types of investments involve varying degrees of risk, and there can be no assurance that any specific investment or strategy will be profitable.
  • No Liability: Neither the author nor Kalkine Group shall be liable for any direct, indirect, incidental, special, or consequential damages arising from the use of or reliance on this information.
  • Do Your Own Research: Readers are strongly encouraged to conduct their own independent research and due diligence before making any investment decisions. Consider consulting with qualified financial, legal, and tax professionals.
  • Market Conditions: Market conditions, company circumstances, and economic factors can change rapidly. Information that was accurate at the time of writing may no longer be current or relevant.

Copyright Notice: This content is the intellectual property of the author. Unauthorized reproduction, distribution, or commercial use is prohibited without express written permission. By reading and using this information, you acknowledge that you have read, understood, and agree to this disclaimer in its entirety.